Markets:

Overview

News

Currencies

International

Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

6.990 -0.420 (-5.67%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

What's Next: WAVE Life Sciences's Earnings Preview ↗

November 11, 2024

Via Benzinga

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

November 04, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

October 30, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

1 Brand-New Big Reason to Buy This Biotech Stock Right Now ↗

October 24, 2024

This stock currently has a good balance of risk and potential rewards.

Via The Motley Fool

Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. ↗

October 21, 2024

Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.

Via Investor's Business Daily

Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio? ↗

October 20, 2024

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Via Benzinga

Wave Life Sciences Rockets 70% on Historic RNA Editing Success

October 18, 2024

Wave Life Sciences' RNA editing advances have generated investor interest as the company strives to become a leading force in the treatment of genetic diseases.

Via MarketBeat

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

October 16, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 16, 2024

Via Benzinga

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans ↗

October 16, 2024

Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license...

Via Benzinga

Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere ↗

October 16, 2024

The company is testing its new technology in patients with a genetic disease that impacts the lungs.

Via Investor's Business Daily

United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday ↗

October 16, 2024

Via Benzinga

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

October 16, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

October 16, 2024

Event will highlight WVE-006 for AATD and Wave’s rapidly advancing, wholly owned pipeline of RNA medicines, including introducing new RNA editing programs and new preclinical data for WVE-007 INHBE...

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics ↗

October 03, 2024

These two could become direct competitors relatively soon.

Via The Motley Fool

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 01, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

September 30, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

September 25, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 25, 2024

Via Benzinga

Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 25, 2024

Via Benzinga

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

September 24, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Crude Oil Gains Over 1%; BioVie Shares Plunge ↗

September 24, 2024

Via Benzinga

Nasdaq Surges 100 Points; Thor Industries Earnings Top Views ↗

September 24, 2024

Via Benzinga

Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug ↗

September 24, 2024

Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular dystrophy patients. Results show improved muscle health, dystrophin production, and...

Via Benzinga

Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday ↗

September 24, 2024

Via Benzinga

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

September 24, 2024

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

September 20, 2024

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

Via MarketBeat

Topics Economy

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating ↗

August 14, 2024

William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.